OSI-906 and Irinotecan in Patients With Advanced Cancer

NCT01016860 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

OTHER

Sponsor class

Stopped This study was discontinued due to a shown lack of efficacy in the investigational agent

Conditions

Colorectal Cancer

Interventions

DRUG: OSI-906
DRUG: irinotecan

Sponsor

University of Colorado, Denver